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ABSTRACT.
Purpose: To investigate the cytotoxic eﬀect of bleomycin, mitomycin C (MMC)
and Fluorouracil (5-FU) in combination with electroporation (EP) on human
conjunctival melanoma (CM) and normal conjunctival cell lines using 2D and 3D
cell culture systems in vitro.
Methods: Two CM (CRMM1, CRMM2) and one normal conjunctival epithelial
cell line (HCjE-Gi) were treated with various EP conditions and increasing
concentrations of 5-FU, MMC and bleomycin. Cell survival was assessed by
MTT viability assay. All cell lines were seeded to create spheroids and were
treated with bleomycin on day 3 and day 8 combined with EP. Spheroids were
collected, ﬁxed in buﬀered formalin and subsequently paraﬃn embedded for
histological assessment of the eﬀects of the treatment on cell viability.
Results: CM cell lines were resistant to electroporation alone and showed a
reduction in cell number only when treated with 1000 Volts/cm and 8 pulses.
HCjE-Gi cells showed higher sensitivity to electric pulses over 750 Volts/cm.
MMC and 5-FU demonstrated a higher cytotoxicity for the HCjE-Gi cell line.
The CM cell lines were resistant to MMC and 5-FU. Bleomycin (1 lg/ml) alone
had no signiﬁcant eﬀect on the HCjE-Gi even when combined with EP conditions
≥750 Volts/cm. In contrast, it signiﬁcantly (p -, paired t-test) reduced cell
viability in the CM cell lines. Spheroids treated with bleomycin and EP showed a
reduction in tumour mass and proliferation rates after treatment.
Conclusion: Our in vitro study using 2D and 3D models indicates that the
application of EP may eﬀectively enhance chemotherapy with bleomycin in CM.
This may oﬀer new viable perspectives for CM treatment.
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Introduction
Conjunctival melanoma (CM) is a rare
malignancy originating from atypical
melanocytes in the conjunctival or
limbal epithelium and comprises 2%
of all ocular melanomas (McCartney
1995). It is associated with a mortality
of 25–30% (Nørregaard et al. 1996;
Seregard 1998; Triay et al. 2009). The
management of CM varies between
ocular oncology centres and has been
based on poor quality evidence of case
series without a standardized therapy
protocol (Damato & Coupland 2009).
Electrochemotherapy (ECT) is a
tumour ablation modality that employs
the eﬀect of short electric pulses to
increase the transport of non-permeant
or poorly permeant anti-cancer drugs
inside cancer cells (Sersa et al. 2008).
This potentiates localized drug cyto-
toxicity, without aﬀecting the sur-
rounding tissue areas. The secondary
actions of ECT include a reduction in
tumour blood ﬂow and a localized
vascular disruption also enhancing
drug eﬃcacy (Gehl et al. 2002; Sersa
et al. 2008; Markelc et al. 2013). A
reversible eﬀect based on high perme-
abilization is desirable (Sersa et al.
2008). Parameters, such as the electric
pulse settings and the cell type, can
have a major inﬂuence on the achieve-
ment of a transient permeabilization
(Mir et al. 2006). The magnitude of the
electric ﬁeld depends on cell type, size,
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orientation and density, pulse duration
and number of pulses (Gehl 2003).
Currently, the standard operating pro-
cedures are guided by recommenda-
tions published by the European
Standard Operating Procedures of
Electrochemotherapy (ESOPE) group
(Mir et al. 2006). The electrical pulses
are applied via plate or needle elec-
trodes depending on the tumour acces-
sibility, number of cancer nodules and
size. The electrical ﬁeld is applied to
each individual pair of adjacent needles
in a sequence controlled by the electro-
porator. The hexagonal and the linear
needle electrodes are suitable for the
treatment of lesions up to 3 cm deep,
whereas lesions up to 1 cm deep can be
treated with ﬁnger electrodes. The use
of plate electrodes is indicated for
exophytic lesions where the pulses are
distributed uniformly between the two
plates. Individual needle electrodes
can be positioned around or within
bone or visceral lesions under viewer
CT or ultrasound guidance (Mir et al.
2006). At present, ECT is used in the
treatment of lesions in patients with
diﬀerent malignancies, for example
metastatic breast cancer (Bourke et al.
2017), metastatic cutaneous melanoma
(Kunte et al. 2017), liver metastases of
carcinomas (Edhemovic et al. 2014),
sarcomas (Marty et al. 2006) as well as
head and neck cancer (Lenzi et al.
2017), not amenable to surgery or
radiofrequency ablation. The treatment
may result in complete remission of the
tumour without the complications that
accompany high chemotherapy doses.
Bleomycin is clinically approved for
use with electroporation (EP) (Orlowski
et al. 1988; Jaroszeski et al. 2000). The
exposure to electric pulses increases the
drug permeation into the cells and,
therefore, the cytotoxicity of the drug
(Cemazar et al. 1998). Mitomycin C
(MMC) has been reported to cause
histopathologic degenerative changes
to the conjunctival epithelium (Salomao
et al. 1999) and has been used as a
primary or adjuvant topical chemother-
apeutic agent for the treatment of CM
(Damato & Coupland 2009). Increased
cytotoxicity ofMMCwithEP inbladder
cancer has been reported in vitro and
in vivo (Vasquez et al. 2000). 5-Fluor-
ouracil (5-FU) is used in the treatment
of a wide range of solid tumours, and its
clinical eﬃcacy in the treatment of
ocular surface squamous neoplasia has
been well documented (Midena et al.
2000; Yeatts et al. 2000). Previous stud-
ies showed promising results with the
combination of 5-FU and EP in ovarian
and bladder carcinoma (Salomao et al.
1999; Saczko et al. 2014). Some data are
available regarding the eﬀect of EP on
uvealmelanoma (Fiorentzis et al. 2018).
The aim of this study was to evalu-
ate the cytotoxic eﬀect of bleomycin, 5-
FU and MMC on two CM cell lines
and one normal epithelial conjunctival
cell line grown in 2D and 3D culture
systems, when used either alone or in
combination with EP.
Materials and Methods
Cell lines and culture
Two CM cell lines, CRMM1 and
CRMM2,were kindly provided byProf.
Dr. Martine Jager, Leiden University
Medical Center, the Netherlands. A
normal conjunctival epithelial cell line,
HCjE-Gi, was kindly provided by Prof.
Dr. Colin Willoughby, University of
Liverpool, UK. All cell lines were tested
for authentication via Short Tandem
Repeat (STR) before initiation of the
experiments and were mycoplasma free
at the time of experimentation. The
CRMM1 and CRMM2 cell lines
derived from a spindle cell tumour orig-
inally located in the bulbar conjunctiva
(Keijser et al. 2007; Nareyeck et al.
2007). The CM cell lines were grown in
Ham’s F-12K (Kaighn’s) Medium (Life
Technologies, Paisley, UK) containing
10% fetal bovine serum (Labtech Inter-
national Ltd, East Sussex, UK) and 1%
Penicillin Streptomycin (Life Technolo-
gies). The normal HCjE-Gi cell line
was grown in Keratinocyte Medium
with Human Recombinant Epidermal
Growth Factor and Bovine Pituitary
Extract (Life Technologies) containing
10% fetal bovine serum (Labtech Inter-
national Ltd). All cell lines were main-
tained as monolayers in 75-cm2 tissue
culture ﬂasks (Fisher Scientiﬁc, Lough-
borough, UK) at 37°C in a humidiﬁed
atmosphere containing 5%CO2 prior to
their use as described below:
Experimental set-up 1
In vitro electrochemotherapy (ECT)
When cells reached 70% conﬂuence,
they were harvested with 0.05% trypsin
(Life technologies), counted and
1 9 106 cells were resuspended in
400 ll of culture medium, with or
without the chemotherapeutic agent.
Each combination was then added to a
4-mm gap electroporation cuvette with
parallel aluminium plate electrodes
(Geneﬂow, Lichﬁeld, UK). A range of
EP conditions were applied to the cell
suspensions using the voltage pulse
generator (CliniporatorTM) designed by
IgeaS.p.A. (Capri, Modena, Italy). All
cells were treated with:
(1) 0 lg/ml, 1-, 5-, 10-, 50- and
100 lg/ml 5-FU;
(2) 0 lg/ml, 1-, 2.5-, 5-, 7.5-, and
10 lg/ml bleomycin and
(3) 0 lg/ml, 0.5-, 1-, 2.5-, 5- and
10 lg/ml MMCcombined with the fol-
lowing EP conditions:
(1) No EP;
(2) 20 square wave electric pulses
(WEP) of 500 Volts/cm strength,
100 ls pulse duration, 5 Hz repetition
frequency;
(3) 40 square WEP of 500 Volts/cm
strength, 100 ls pulse duration, 5 Hz
repetition frequency;
(4) 8 square WEP of 750 Volts/cm
strength, 100 ls pulse duration, 5 Hz
repetition frequency;
(5) 20 square WEP of 750 Volts/cm
strength, 100 ls pulse duration, 5 Hz
repetition frequency;
(6) 8 square WEP of 1000 Volts/cm
strength, 100 ls pulse duration, 5 Hz
repetition frequency.
Following treatment, 2 9 104 cells
were transferred into six wells of a 96-
well plate for each treatment condition
and the appropriate culture medium
was added up to a maximum volume of
100 ll. The plates were then incubated
for 24 and 72 hr, allowing the cells to
attach and grow.
The protocol was conducted for
both CM cell lines and the HCjE-Gi
cells. Each experiment was performed
on three diﬀerent dates, giving a total
of 18 technical replicates for each ECT
condition.
MTT viability assay
Cell viability was examined using the
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) tetra-
zolium reduction assay (MTT; Sigma-
Aldrich, Dorset, UK). Culture medium
was aspirated from each well after 24
or 72 hr, and the MTT stock solution
(5 mg/ml) was added according to the
manufacturer’s protocol (90 ll med-
ium and 10 ll MTT). All plates were
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incubated at 37° for 4 hr. The solution
was then removed, and the formazan
formed in the cells was dissolved using
100 ll of a 1:1 solution of dimethyl
sulfoxide (DMSO; Sigma-Aldrich) and
2-propanol (isopropanol; Sigma-
Aldrich). The absorbance of formazan
was determined at 570 nm on a plate
reader (SPECTRAFLUOR, Tecan,
Austria). The viability of the treated
cells was expressed relative to untreated
control cells. Relative EC50 values
were calculated for each of the drugs
tested in the cell lines examined using a
freeware tool (https://www.aatbio.c
om/tools/ec50-calculator/). The rela-
tive EC50 value calculated represents
the estimated drug concentration that
caused cell death halfway between the
baseline (i.e. no drug present) and the
maximal response to the drug that was
observed. For this relative estimation,
at least one additional value beyond
the maximal cell death observed was
required. This was not possible for
CRMM1 and CRMM2 cells treated
with bleomycin and CRMM1 cells
treated with MMC (Table 1), where
these criteria were not met.
Experimental set-up 2
Ultralow attachment plate
The two above-mentioned CM cell
lines (CRMM1 and CRMM2) and the
normal conjunctival epithelial cells
(HCjE-Gi) were cultured using Corn-
ing 96-well ultralow attachment plates
(Sigma-Aldrich). Cells were seeded at
5 9 103 cells/well to form spheroids at
37°C in a humidiﬁed atmosphere con-
taining 5% CO2. The culture medium
was exchanged every other day. To
remove culture medium, the end of a
pipette tip was placed at the neck
region of the well to avoid spheroid
disruption. Data that are not included
in this paper indicated a continuous
growth of the spheroids until day 3, a
stable size until day 7 and a further
growth on day 8. The size of the
spheroids was maintained until day
30. Combining the results of the Exper-
imental set-up 1, the spheroids were
treated with two bleomycin concentra-
tions (1 lg/ml and 2.5 lg/ml) for 24 hr
on day 3 and day 8. Three EP condi-
tions were applied using the voltage
pulse generator (CliniporatorTM)
designed by IgeaS.p.A. (Capri, Mod-
ena, Italy). Details of all experimental
conditions are given below.
(1) No EP;
(2) 20 square WEP of 500 Volts/cm
pulse strength, 100 ls pulse duration,
5 Hz repetition frequency;
(3) 8 square WEP of 750 Volts/cm
pulse strength, 100 ls pulse duration,
5 Hz repetition frequency.
The EP was conducted in the wells
using two ﬂat parallel stainless steel
electrodes on day 3. At 24 and 72 hr
following treatment, the spheroids were
collected, ﬁxed in 10% neutral buﬀered
formalin (Leica Microsystems UK Ltd,
Milton Keynes, UK) and prepared for
histological and immunohistochemical
(IHC) analysis.
Histology and Immunohistochemistry
Molten agar was added to the forma-
lin-ﬁxed spheroids, collected at the
bottom of a microfuge tube and
allowed to set. The agar-embedded
spheroids were then removed from the
tubes and placed in tissue cassettes
before being loaded onto the BAYER
VIP E300 tissue processor. Following
dehydration, agar-embedded spheroids
were orientated in wax blocks for
sectioning. 4-lm sections were cut onto
XtraTM adhesive slides (Leica Microsys-
tems UK Ltd) and stained with haema-
toxylin and eosin (H&E) according to
standard protocols. The spheroids were
evaluated for their size, shape regular-
ity, the presence/absence of central
spheroid necrosis, the presence/absence
of apoptotic cells and the presence/
absence of adjacent dispersed cells
surrounding them.
IHC was performed to detect the Ki-
67 antigen using a mouse anti-human
Ki67 antibody (Clone MM1; Leica
Microsystems UK Ltd) at a dilution
of 1:100 and a Dako EnVision Flex kit
(Agilent Technologies LDA UK Lim-
ited, Cheadle, UK) according to the
manufacturer’s instructions following
dewaxing and heat-induced epitope
retrieval in the Dako pretreatment
module; slides were incubated in a
high-pH bath containing EnVisionTM
FLEX target retrieval solution (Tris/
EDTA buﬀer pH9.0) at 96°C for
20 min. Bound antibody was visualized
with EnVisionTMFLEX 3,30-diamino-
benzidine (DAB+). Sections were coun-
terstained with Mayer’s haematoxylin
(VWR International Ltd, Lutterworth,
UK), blued with Scott’s tap water
(Leica Microsystems UK Ltd) and
mounted with DPX mountant (Sigma,
St. Louis, Mo, USA). Human tonsil
tissue was used as a positive control.
Negative control sections were incu-
bated with mouse IgG1. ImageJ2 (NIH
Image, 2009) was used as a processing
program for the multidimensional
image analysis and for the Ki-67 pro-
liferation evaluation.
Results
Experimental set-up 1
In 2D culture, the most signiﬁcant
eﬀects of 5-FU, bleomycin and MMC
to reduce cell number were seen 72 hr
following incubation with each of the
agents alone (Fig. 1); EC50 values are
shown in Table 1.
HCjE-Gi cells were most sensitive to
MMC with an EC50 of 0.58 lg/ml. EP
had no signiﬁcant eﬀect to enhance the
eﬃcacy of 5-FU or MMC in HCjE-Gi
cells after 72 hr (Fig. 1). However, EP
of 750 Volts/cm for 8 pulses increased
the sensitivity of HCjE-Gi cells to
bleomycin (Fig. 1), such that the
EC50 for this drug was reduced from
3.36 lg/ml to 1.42 lg/ml. This was not
further enhanced by either increasing
the number of pulses or increasing the
voltage to 1000 Volts/cm.
CRMM1 cells were most sensitive to
5-FU with an EC50 of 1.07 lg/ml, and
Table 1. Relative EC50 values for conjunctival melanoma and normal conjunctival cell lines
treated with 5FU, MMC and bleomycin for 72 hr.
EC50 values (lg/ml)
5FU MMC Bleomycin
CRMM1 1.07 NC NC
CRMM2 16.18 0.98 NC
HCjE 10.97 0.58 3.36
The relative EC50 values represent the estimated drug concentration causing cell death halfway
between the baseline (i.e. no drug present) and the maximal response to the drug.
NC = noncalculable.
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the cytotoxic eﬀect of this drug was not
further enhanced by EP (Fig. 1).
Similarly, EP did not further increase
the sensitivityofCRMM1cells toMMC.
CRMM2 cells were most sensitive to
MMC with an EC50 of 0.98 lg/ml,
eﬀects that were not further enhanced
by EP (Fig. 1). Interestingly, EP
≥750 Volts/cm further increased the
sensitivity of CRMM2 cells to only
the lowest dose of 5-FU tested, 1 lg/ml
(Fig. 1).
CRMM1 and CRMM2 cells were
largely resistant to the cytotoxic eﬀects
of bleomycin alone; however, this was
enhanced in both cell lines by EP
(Fig. 1). EP conditions of ≥750 Volts/
cm signiﬁcantly enhanced the cyto-
toxic eﬀects of bleomycin such that
even at the lowest dose tested, 1 lg/
ml, cell numbers were maximally
reduced compared with cells treated
with this dose of bleomycin alone;
6.5% cell viability compared with
73.1% (p -, paired t-test) in CRMM1
cells, and 5.9% cell viability compared
with 76.1% (p -, paired t-test) in
CRMM2 cells. This enhanced cyto-
toxic eﬀect of 1 lg/ml bleomycin in
the presence of 750 Volts/cm was not
observed in the HCjE cells.
Experimental set-up 2
Based on the results of the experi-
ments performed in 2D culture, a
Fig. 1. Cytotoxicity of 5-FU, MMC and bleomycin with and without electroporation 72 hr following treatment in (A) HCjE normal conjunctival
cells (B) CRMM1 and (C) CRMM2 conjunctival melanoma cells. Bars within each electroporation condition represent increasing concentrations of
the drug from baseline, that is cells alone. The black bars show the eﬀect of increasing electroporation alone on cell viability. Enhanced eﬀects of
bleomycin to reduce CRMM1 and CRMM2 viability can clearly be seen with increasing electroporation; however, this is less evident for 5FU and
MMC. HCjE cells are sensitive to increasing concentrations of 5FU, MMC and bleomycin irrespective of the electroporation conditions employed.
Values are the mean  SEM.
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Fig. 2. Decreased growth fraction on day 3 as well as on day 8, after treatment with 1 lg/ml bleomycin and ECT with 750 Volts/cm for 8 pulses but
not for bleomycin alone for CRMM1 cell line. Reduction in the spheroid mass with necrosis and loss of cell deﬁnition with the formation of conﬂuent
cells with multiple nuclei.
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concentration of 1 lg/ml bleomycin
and the electric ﬁeld condition of
750 Volts/cm with 8 pulses, 100 ls
pulse duration, 5 Hz repetition fre-
quency were applied to a 3D spheroid
model.
Bleomycin alone had only a limited
eﬀect on cell viability when examining
the H&E-stained sections for degener-
ative changes. For example, no cyto-
toxic eﬀect of bleomycin could be seen
in CRMM1 and HCjE-Gi cell lines on
day 3 (Figs 2,4). However, a cytotoxic
eﬀect of 1 lg/mg bleomycin without
EP was noted on day 3 for the
CRMM2 (Fig. 3).
When combining 1 lg/ml bleomycin
with EP at 750 Volts/cm for 8 pulses, a
Fig. 3. Eﬀect of bleomycin alone (1 lg/ml) and after combination with 750 Volts/cm and 8 pulses on spheroid viability on day 3 and day 8 for
CRMM2 cell line. Increased cell death 24 hr after combined treatment on day 3 as well as on day 8.
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reduction in the spheroid mass together
with necrosis, a loss of cell deﬁnition
and the formation of conﬂuent cells
with multiple nuclei was observed. This
was noted 24 hr following treatment
on day 8 in all cell lines (Figs 2–4). In
terms of a decreased spheroid size and
histological changes, this appeared to
be most apparent in the CRMM2 cells
following ECT. Furthermore, there
was a decreased Ki-67 growth fraction
in all three cell lines on day 3 as well as
on day 8 compared to the ﬁndings
without treatment (Figs 2–4). The
combined treatment led to 89.5%
reduction (p -, paired t-test) in the
proliferation of the CRMM1 and to
88.1% reduction (p -, paired t-test) of
the CRMM2 on day 3. On the other
hand, the bleomycin treatment alone
showed an increase in the Ki-67
Fig. 4. Treatment results of bleomycin (1 lg/ml) with ECT (750 Volts/cm and 8 pulses) on spheroids for HCjE-Gi cell line. Decreased cell death
24 hr after treatment on day 3 of normal epithelial conjunctival cells.
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staining by 61.6% of the CRMM1 cells
and 59.5% of the CRMM2 cells.
Discussion
Presented here are novel results inves-
tigating the application of ECT in CM
using 2D and 3D cell culture models.
ECT constitutes a new therapeutic
strategy, eﬀective even with highly
reduced doses and time exposure of
standard chemotherapeutic drug pro-
tocols. Indeed, the application of ECT
may signiﬁcantly reduce adverse drug
side-eﬀects, including toxic eﬀects to
surrounding normal tissues. The mech-
anisms of increasing drug eﬃcacy of
ECT are dependent on various factors,
such as the pulse duration, amplitude
and the number of delivered pulses
(Mir et al. 1991).
Current treatments of CM include
surgical excision, cryotherapy adjunc-
tive plaque therapy and topical
chemotherapy for residual conjunctival
melanoma in situ (Kenawy et al. 2013).
The topical agents used include MMC
and 5‑FU (Yeatts et al. 1995; Salomao
et al. 1999; Midena et al. 2000; Kim &
Abramson 2008), and both are associ-
ated with signiﬁcant side-eﬀects, mainly
due to their toxicity on corneal stem
cells. The latter can cause limbal stem
cell failure leading to in some cases in
corneal erosion or ulceration, scleral
ulceration, and in advanced cases patho-
logical changes of the anterior uvea
(Yeatts et al. 1995; Salomao et al.
1999). Consequently, alternative thera-
pies are being investigated for CM.
Bleomycin is widely used to inhibit
cancer cell proliferation (Domenge
et al. 1996). It is a water-soluble antibi-
otic, and its cytotoxicity is associated
with the induction of single- and dou-
ble-strand DNA breaks (Byrnes et al.
1990). Due to its high molecular weight
(MW 1487.49), bleomycin cannot
easily penetrate the cell membrane
and enter the cell, limiting bleomy-
cin’s cytotoxic eﬀect and clinical appli-
cability (Roy & Horwitz 1984; Takita
1984). ECT allows the penetration of
molecules into the cytoplasm through
the formation of reversible pores in the
cell membrane (Gehl 2003; Mir et al.
2006).
In 2D culture of CM cell lines, we
demonstrated that electroporation did
not signiﬁcantly enhance the cytotoxic-
ity of MMC and 5-FU when compared
with HCjE-Gi normal conjunctival
cells. However, ECT combined with
1 lg/ml bleomycin at 750 Volts/cm
with 8 pulses reduced cell viability of
the CM cell lines, without inﬂuencing
cell viability of the normal conjunctival
cells.
The aim of the second part of our
studywas to develop a 3D in vitromodel
of CM cells, which would more accu-
rately mimic in vivo conditions and
enable successful EP and ECT. Cancer
cell lines traditionally grown as mono-
layers for investigating the mechanisms
and treatment of cancer fail to repro-
duce the physiological phenomena
observed in vivo (Desoize 2000). They
do not reproduce the morphology and
biochemical features that cells possess in
the original tissue. As an alternative, 3D
in vitro models of cells oﬀer the possi-
bility to study diﬀerent parameters
under conditions that more closely
resemble the in vivo situation. In the
2D in vitro model that we applied in
Experiment 1, only the combination of
bleomycin together with ECT signiﬁ-
cantly reduced cell viability inCRMM1,
CRMM2 and HCjE-Gi cell lines. How-
ever, the eﬀect of the combined treat-
ment on the spheroid viability was lower
in the HCjE-Gi cell line. Because MMC
and 5-FU molecules are smaller than
bleomycin molecules (MMC, MW
334.33; 5-FU, MW 130.8), they pass
easily through the cellular membrane
and the inﬂuence of electroporation on
their cytotoxic eﬀect was negligible
(Yeatts et al. 1995; Salomao et al.
1999). Therefore, bleomycin in combi-
nation with the optimal ECT conditions
from the ﬁrst part of our study was used
to evaluate the cytotoxic eﬀect in the 3D
model of CRMM1, CRMM2 and
HCjE-Gi cell lines.We show for the ﬁrst
time that EP sensitizes CM cells to doses
that have aminimal eﬀect on the normal
conjunctival cells on 2D and 3Dmodels.
Further development of this plat-
form using more advanced in vitro 3D
experiments as well as in preclinical
animal models (e.g. chick embryo
(Kalirai et al. 2015), or murine CM
models (de Waard et al. 2015)) will
facilitate the acceptance of irreversible
electroporation (IRE) as a viable can-
cer therapy.
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